Inositol is a type of sugar alcohol that is often categorized as a member of the B-vitamin complex, although it is not a vitamin itself. It is a naturally occurring compound found in various forms, with Myo-inositol and D-chiro-inositol being the most commonly studied and supplemented. Inositol plays a crucial role in several biological processes, including cell membrane formation, fat metabolism, and insulin signal transduction.

Chemically, inositol is a cyclic polyol with six carbon atoms, each of which has a hydroxyl group attached. This structure allows it to be involved in a variety of cellular processes. Inositol is found in many foods, particularly in fruits, beans, grains, and nuts. Additionally, the human body can synthesize inositol from glucose, making it an essential component of cellular health and function.

Inositol is widely recognized for its importance in cellular signaling. It acts as a precursor for various signaling molecules, including inositol triphosphate (IP3) and diacylglycerol (DAG), which are essential for transmitting signals within cells. These signaling pathways are involved in numerous physiological processes, such as regulating calcium levels within cells, which is critical for muscle contraction, neurotransmitter release, and hormone secretion.

Given its diverse roles in the body, inositol has garnered attention for its potential therapeutic benefits. It is often used as a dietary supplement to support mental health, hormonal balance, and metabolic functions. Research suggests that inositol may be beneficial for conditions like polycystic ovary syndrome (PCOS), insulin resistance, and certain mood disorders, highlighting its multifaceted role in promoting overall health and well-being.

Inositol is used for a variety of health conditions, primarily due to its role in cellular signaling, fat metabolism, and insulin regulation. One of the most well-documented uses of inositol is in the management of polycystic ovary syndrome (PCOS). Studies have shown that inositol, particularly in the forms of Myo-inositol and D-chiro-inositol, can help improve insulin sensitivity, reduce testosterone levels, and enhance ovulation in women with PCOS. A systematic review and meta-analysis published in the "Journal of Diabetes and its Complications" found that Myo-inositol supplementation significantly lowered the risk of gestational diabetes mellitus (GDM) in pregnant women at high risk for this condition.

Inositol is also used to alleviate symptoms of mood disorders such as anxiety and depression. Research has indicated that high doses of inositol can reduce anxiety symptoms, making it comparable in potency to some pharmaceutical interventions. For instance, a study published in the "American Journal of Psychiatry" demonstrated that inositol effectively reduced panic attacks and agoraphobia severity in patients with panic disorder. Additionally, inositol has shown promise in treating depressive symptoms, although its effects may be less potent compared to its efficacy in anxiety disorders.

Another significant application of inositol is in the management of metabolic conditions, including insulin resistance and type 2 diabetes. Inositol has been shown to improve glycemic control by enhancing insulin sensitivity. A meta-analysis of randomized controlled trials published in "Clinical Nutrition" revealed that inositol supplementation decreases blood glucose levels and improves insulin sensitivity independently of weight loss. This makes it a valuable supplement for individuals struggling with metabolic syndrome or those at risk of developing diabetes.

Inositol is also explored for its potential benefits in improving fertility, particularly in women with PCOS. Studies have shown that supplementation with inositol can increase ovulation rates and improve oocyte quality, thereby enhancing fertility outcomes. For example, a study in "Fertility and Sterility" found that Myo-inositol combined with folic acid improved oocyte quality in women undergoing intracytoplasmic sperm injection (ICSI) cycles.

Overall, the body of research supports the use of inositol for a range of conditions related to hormonal balance, mental health, and metabolic function. Its multifaceted role in cellular processes makes it a promising supplement for improving overall health and well-being.

Inositol works through multiple mechanisms, primarily involving its role in cellular signaling and metabolism. One of the key functions of inositol is its involvement in the phosphatidylinositol (PI) signaling pathway. Inositol acts as a precursor to various phosphoinositides, which are critical for the formation of second messengers like inositol triphosphate (IP3) and diacylglycerol (DAG). These second messengers are essential for transmitting signals from receptors on the cell surface to intracellular targets, thus regulating numerous cellular processes.

The PI signaling pathway plays a crucial role in regulating calcium levels within cells. When a receptor on the cell surface is activated, it triggers the production of IP3, which then binds to receptors on the endoplasmic reticulum, causing the release of calcium ions into the cytoplasm. This increase in intracellular calcium is vital for various cellular functions, including muscle contraction, neurotransmitter release, and hormone secretion.

Inositol also significantly impacts insulin signaling and glucose metabolism. Myo-inositol and D-chiro-inositol are involved in the insulin signaling cascade, which enhances the activity of insulin receptors and improves insulin sensitivity. By facilitating the uptake of glucose into cells, inositol helps lower blood glucose levels and improves overall glycemic control. This is particularly beneficial for individuals with insulin resistance or type 2 diabetes. Studies have shown that inositol supplementation can reduce fasting blood glucose and improve the homeostasis model assessment of insulin resistance (HOMA-IR) index.

Furthermore, inositol has been found to modulate neurotransmitter systems, which is why it is used in the context of mental health. It has been shown to affect the serotonin system, which is involved in mood regulation. Inositol's ability to influence serotonin receptors and uptake mechanisms may underlie its efficacy in treating conditions like anxiety, depression, and panic disorders. For example, research published in the "Journal of Clinical Psychopharmacology" demonstrated that inositol could reduce the frequency of panic attacks in patients with panic disorder.

Inositol's impact on hormonal balance is another significant aspect of its mechanism of action. In women with polycystic ovary syndrome (PCOS), inositol helps to restore normal ovarian function by improving insulin sensitivity and reducing androgen levels. This, in turn, can enhance ovulation and improve fertility outcomes. Studies have shown that Myo-inositol and D-chiro-inositol can reduce testosterone levels and improve menstrual regularity in women with PCOS.

Overall, inositol works through a combination of mechanisms that involve cellular signaling, insulin sensitivity, neurotransmitter modulation, and hormonal regulation. Its multifaceted actions make it a versatile and effective compound for addressing various health conditions.

Inositol is utilized in both men's and women's health, but the specific applications and benefits can differ based on the unique physiological needs and common health issues faced by each gender. In women's health, inositol is predominantly used for conditions related to hormonal balance and reproductive health, while in men's health, it is often employed for metabolic and mental health benefits.

In women, one of the primary uses of inositol is for the management of polycystic ovary syndrome (PCOS). PCOS is a hormonal disorder that affects a significant number of women of reproductive age and is characterized by insulin resistance, elevated androgen levels, and irregular menstrual cycles. Inositol, particularly Myo-inositol and D-chiro-inositol, has been shown to improve insulin sensitivity, reduce testosterone levels, and enhance ovulatory function. Studies have demonstrated that supplementation with these forms of inositol can lead to more regular menstrual cycles, improved fertility, and better overall hormonal balance. For instance, a study published in "Fertility and Sterility" found that Myo-inositol combined with folic acid improved oocyte quality and increased pregnancy rates in women undergoing assisted reproductive technologies.

Inositol is also used in women to reduce the risk of gestational diabetes mellitus (GDM). Pregnant women with a high risk of developing GDM, such as those with a family history of type 2 diabetes or who are overweight, can benefit from inositol supplementation. Research published in the "Journal of Diabetes and its Complications" indicates that Myo-inositol can significantly lower the incidence of GDM, thereby promoting a healthier pregnancy and reducing complications for both mother and baby.

In men, inositol is primarily utilized for its effects on metabolic health and mental well-being. Men often use inositol to improve insulin sensitivity and manage conditions like metabolic syndrome and type 2 diabetes. By enhancing insulin signaling, inositol helps regulate blood glucose levels and reduce the risk of diabetes-related complications. A study in "Clinical Nutrition" showed that inositol supplementation could decrease fasting blood glucose levels and improve insulin sensitivity in healthy subjects, highlighting its potential benefits for men at risk of metabolic disorders.

Inositol is also used to support mental health in men, particularly for conditions such as anxiety and depression. Research has shown that high doses of inositol can reduce anxiety symptoms and improve mood, making it a valuable supplement for men dealing with stress and mental health challenges. For example, a study in the "American Journal of Psychiatry" found that inositol was effective in reducing panic attack frequency and severity, providing a natural alternative for managing anxiety disorders.

Overall, while both men and women can benefit from inositol supplementation, the specific applications and benefits often align with the distinct health concerns prevalent in each gender. Women primarily use inositol for hormonal and reproductive health, while men focus on metabolic and mental health benefits. This versatility makes inositol a valuable addition to the health regimens of both men and women.

The appropriate dosage of inositol can vary widely depending on the condition being treated and the specific needs of the individual. In clinical studies and therapeutic settings, dosages have ranged from as low as 200 mg to as high as 18 grams per day. Therefore, determining the right dosage requires a careful assessment of the intended use, the form of inositol being used, and individual patient factors.

For the management of polycystic ovary syndrome (PCOS), a common dosage is 2 to 4 grams of Myo-inositol daily, often combined with folic acid. This dosage has been shown to improve insulin sensitivity, reduce androgen levels, and enhance ovulatory function. A study published in "Fertility and Sterility" demonstrated that a daily dose of 4 grams of Myo-inositol combined with 400 mcg of folic acid significantly improved oocyte quality in women undergoing assisted reproductive technologies.

In cases of mental health conditions such as anxiety and depression, higher doses of inositol are typically used. Research has indicated that doses ranging from 12 to 18 grams per day can be effective in reducing symptoms of anxiety and panic disorders. For example, a study in the "American Journal of Psychiatry" found that a dose of 12 grams per day of inositol significantly reduced panic attack frequency and severity. It's important to note that such high doses should be taken under medical supervision due to the potential for gastrointestinal side effects.

For metabolic health, including the management of insulin resistance and type 2 diabetes, dosages of Myo-inositol around 2 grams per day have been commonly used. A meta-analysis published in "Clinical Nutrition" found that inositol supplementation at this dosage could improve insulin sensitivity and reduce fasting blood glucose levels. This makes it a valuable option for individuals looking to improve their metabolic profile.

Pregnant women at risk of developing gestational diabetes mellitus (GDM) may benefit from a dosage of 2 grams of Myo-inositol taken twice daily, often starting in the first trimester and continuing throughout pregnancy. Research published in the "Journal of Diabetes and its Complications" has shown that this regimen can significantly reduce the incidence of GDM and improve pregnancy outcomes.

It's essential to start with a lower dose and gradually increase it to the recommended therapeutic level to minimize any potential side effects. Additionally, individuals should consult with a healthcare provider before starting inositol supplementation, especially if they are pregnant, nursing, or have any preexisting medical conditions.

In summary, the optimal dosage of inositol varies depending on the condition being treated and individual factors. Standard dosages range from 2 grams per day for metabolic and reproductive health to 12-18 grams per day for mental health conditions. Always consult a healthcare provider to determine the most appropriate dosage for your specific needs.

Inositol is generally considered safe and well-tolerated, especially when taken at standard doses. However, like any supplement or medication, it can cause side effects in some individuals. The severity and type of side effects can vary depending on the dosage and individual sensitivity.

One of the most commonly reported side effects of inositol is gastrointestinal discomfort. This can include symptoms such as nausea, bloating, gas, and diarrhea. These side effects are more likely to occur at higher doses, such as those used in studies for treating mental health conditions (12-18 grams per day). For instance, research published in the "Journal of Clinical Psychopharmacology" noted that while inositol was effective in reducing panic attacks, some participants experienced gastrointestinal issues.

Another potential side effect is dizziness, which has been reported in some individuals taking inositol supplements. This side effect is also more common at higher doses and may be transient, resolving on its own as the body adjusts to the supplement.

Inositol can also cause mild headaches in some users. This is generally a rare side effect and is usually not severe. Hydration and gradual dosage increases can help mitigate this issue.

For women with polycystic ovary syndrome (PCOS) taking inositol to improve insulin sensitivity and hormonal balance, there have been occasional reports of fatigue and mood swings. These side effects are typically mild and temporary. A study published in "Fertility and Sterility" found that most women tolerate inositol well, with only a few experiencing minor side effects.

In rare cases, individuals may experience allergic reactions to inositol supplements. Symptoms of an allergic reaction can include itching, rash, swelling, and difficulty breathing. If any of these symptoms occur, it is crucial to seek medical attention immediately.

It is also worth noting that while inositol is generally safe, it may interact with other medications or supplements. Therefore, it is advisable to consult with a healthcare provider before starting inositol, particularly if you are taking other medications or have underlying health conditions.

In summary, the main side effects of inositol are gastrointestinal discomfort, dizziness, mild headaches, fatigue, and mood swings. These side effects are generally mild and temporary, especially when the supplement is taken at standard doses. However, it is important to consult with a healthcare provider before starting inositol supplementation to ensure it is safe and appropriate for your individual health needs.

While inositol is generally considered safe and well-tolerated for most people, there are certain groups of individuals who should exercise caution or avoid taking inositol supplements altogether. Understanding these contraindications is essential to ensure safe and effective use.

Firstly, individuals with bipolar disorder should be cautious with inositol supplementation. Some studies suggest that inositol may exacerbate manic symptoms in individuals with bipolar disorder, particularly when taken in high doses. A study published in "Bipolar Disorders" found that while inositol could be beneficial for depressive symptoms, it might also trigger manic episodes in some patients. Therefore, it is crucial for individuals with bipolar disorder to consult their healthcare provider before considering inositol supplementation.

Pregnant and breastfeeding women should also consult their healthcare provider before starting inositol supplements. Although inositol is sometimes recommended to reduce the risk of gestational diabetes mellitus (GDM) and improve insulin sensitivity during pregnancy, the safety and efficacy of inositol supplementation during pregnancy and lactation are not fully established. Healthcare providers can offer personalized advice based on individual health status and needs.

Individuals with kidney disorders should be cautious when considering inositol supplementation. Since inositol is metabolized and excreted by the kidneys, those with impaired kidney function may have difficulty processing the supplement, leading to potential accumulation and adverse effects. It is vital for individuals with kidney issues to seek medical advice before starting inositol.

People with allergies to inositol or any of the ingredients in inositol supplements should avoid taking these products. Although allergic reactions to inositol are rare, they can occur and may manifest as itching, rash, swelling, or difficulty breathing. If any allergic symptoms arise, it is essential to discontinue use and seek medical attention immediately.

Those taking certain medications should also consult their healthcare provider before starting inositol supplements. Inositol may interact with specific drugs, including lithium and other medications used to treat psychiatric conditions. A healthcare provider can assess potential interactions and adjust treatment plans accordingly to ensure safety and efficacy.

Lastly, individuals with a history of gastrointestinal issues, such as irritable bowel syndrome (IBS) or severe gastrointestinal sensitivity, should use inositol with caution. High doses of inositol can cause gastrointestinal discomfort, including bloating, gas, and diarrhea. Starting with a lower dose and gradually increasing it can help mitigate these side effects, but it is essential to monitor for any adverse reactions.

In summary, while inositol is generally safe for most people, it should be used with caution or avoided by individuals with bipolar disorder, pregnant and breastfeeding women, those with kidney disorders, people with allergies to inositol, individuals taking certain medications, and those with a history of gastrointestinal issues. Consulting a healthcare provider before starting inositol supplementation is crucial to ensure it is safe and appropriate for individual health needs.

Yes, inositol supplements can interact with certain medications, and it is important to be aware of these potential interactions to ensure safe and effective use. Here are some key medications that may interact with inositol:

1. Lithium: Inositol is known to interact with lithium, a medication commonly used to treat bipolar disorder. Lithium affects inositol metabolism, and inositol supplementation can alter the effects of lithium therapy. Specifically, inositol can counteract some of the therapeutic effects of lithium by replenishing the inositol levels that lithium depletes. A study published in "Bipolar Disorders" highlighted that while inositol might benefit depressive symptoms, it could potentially exacerbate manic symptoms in individuals taking lithium. Therefore, it is crucial for individuals on lithium therapy to consult their healthcare provider before taking inositol supplements.
2. Selective Serotonin Reuptake Inhibitors (SSRIs): Inositol can also interact with SSRIs, a class of medications used to treat depression and anxiety disorders. SSRIs work by increasing serotonin levels in the brain, and inositol is involved in the phosphatidylinositol signaling pathway, which can influence serotonin receptor activity. While some studies suggest that inositol may enhance the effects of SSRIs, others indicate that it could potentially alter their efficacy. A study in the "Journal of Clinical Psychopharmacology" found that inositol might improve the therapeutic effects of SSRIs, but these interactions require careful monitoring by a healthcare provider.
3. Carbamazepine and Valproate: These medications are anticonvulsants often used to treat epilepsy and bipolar disorder. Inositol can potentially interact with these drugs by influencing the inositol phosphate pathway, which is involved in mood regulation and seizure activity. While specific interactions are not well-documented, it is advisable for individuals taking carbamazepine or valproate to consult their healthcare provider before starting inositol supplements.
4. Antipsychotic Medications: Inositol may interact with antipsychotic medications, which are used to treat conditions such as schizophrenia and bipolar disorder. These medications can affect the inositol signaling pathway, and supplementation with inositol might alter the therapeutic effects or side effects of antipsychotics. A study in "European Neuropsychopharmacology" suggested that inositol could influence the efficacy of antipsychotic medications, necessitating close monitoring and consultation with a healthcare provider.
5. Blood Sugar-Lowering Medications: Inositol is known to improve insulin sensitivity and lower blood glucose levels, which can interact with medications used to manage diabetes, such as metformin, insulin, and other antidiabetic drugs. Combining inositol with these medications could enhance their blood sugar-lowering effects, potentially leading to hypoglycemia. A study published in "Clinical Nutrition" highlighted the need for careful monitoring of blood glucose levels when combining inositol with antidiabetic medications.

In summary, while inositol supplements are generally safe, they can interact with medications such as lithium, SSRIs, anticonvulsants, antipsychotics, and blood sugar-lowering medications. It is essential for individuals taking these medications to consult their healthcare provider before starting inositol supplements to ensure safe and effective use. Healthcare providers can assess potential interactions, adjust dosages, and provide personalized recommendations based on individual health needs.

Inositol is naturally found in a variety of foods, and consuming a diet rich in these foods can help ensure adequate intake. Here are some of the best dietary sources of inositol:

1. Fruits: Citrus fruits such as oranges, grapefruits, and lemons are excellent sources of inositol. Additionally, cantaloupe and cantaloupe juice are particularly high in inositol. Bananas also contain significant amounts of this compound, making them a convenient and nutritious option.
2. Vegetables: Vegetables such as beans, peas, and lentils are rich in inositol. Green leafy vegetables like spinach and kale also contain considerable amounts. These vegetables provide not only inositol but also a range of other essential nutrients and fibers.
3. Whole Grains: Whole grains such as brown rice, oats, and whole wheat products are good sources of inositol. Consuming whole grain foods instead of refined grains can help boost your inositol intake while providing additional health benefits such as improved digestion and better blood sugar control.
4. Nuts and Seeds: Nuts, particularly almonds, walnuts, and peanuts, are rich in inositol. Seeds such as sesame seeds and sunflower seeds also contain significant amounts. These foods are great snacks and can be added to various dishes to increase your inositol intake.
5. Legumes: Beans, lentils, chickpeas, and soybeans are excellent sources of inositol. Soy-based products like tofu and tempeh also provide considerable amounts of inositol, making them a great addition to a balanced diet.
6. Animal Products: While plant-based foods are the primary sources of inositol, certain animal products also contain this compound. Organ meats such as liver and heart are particularly high in inositol. Eggs and milk also provide moderate amounts of inositol.
7. Supplements: For individuals who may not get enough inositol from their diet, supplements are available in various forms. Myo-inositol and D-chiro-inositol are the most commonly used forms in supplements. These can be found in powder, capsule, and tablet forms. Supplements are particularly useful for individuals with specific health conditions like PCOS, where higher doses of inositol are needed to achieve therapeutic benefits.

In summary, the best sources of inositol are a variety of fruits, vegetables, whole grains, nuts, seeds, legumes, and certain animal products. Incorporating these foods into your diet can help ensure you receive adequate inositol intake for overall health. For those who require higher doses for therapeutic purposes, inositol supplements are a convenient and effective option. Always consult with a healthcare provider before starting any new supplement regimen to ensure it is appropriate for your individual health needs.

Inositol is available in various forms, each catering to different needs and preferences. Understanding the different forms can help you choose the most suitable option for your specific health goals. Here are the primary forms of inositol:

1. Powder: Inositol powder is one of the most common and versatile forms. It can be easily mixed with water, juice, or other beverages, making it a convenient option for those who prefer to incorporate it into their daily routine. This form is particularly useful for individuals who require higher doses, such as those with polycystic ovary syndrome (PCOS) or mental health conditions. The powder form allows for flexible dosing, making it easy to adjust the amount as needed. Studies, including those published in "Fertility and Sterility," often use inositol powder for its ease of administration and accurate dosing.
2. Capsules and Tablets: Inositol is also available in capsule and tablet forms. These are convenient for those who prefer a pre-measured dose and ease of portability. Capsules and tablets are often used for standardized dosages, typically ranging from 500 mg to 2000 mg per serving. This form is particularly useful for individuals who prefer not to measure out powder and want a quick and easy way to take their supplements.
3. Liquid: Liquid inositol supplements are less common but available. They can be useful for individuals who have difficulty swallowing pills or prefer a liquid form for ease of ingestion. Liquid forms can be mixed with beverages or taken directly, offering flexibility in administration.
4. Combined Formulations: Inositol is often found in combined formulations with other beneficial nutrients. For example, Myo-inositol is frequently combined with D-chiro-inositol in a 40:1 ratio, which has been shown to be particularly effective for managing PCOS. Additionally, inositol supplements may be combined with folic acid, vitamins, or other minerals to enhance their overall efficacy. A study in "European Review for Medical and Pharmacological Sciences" highlighted the benefits of combined formulations in improving hormonal and metabolic health.
5. Myo-Inositol and D-Chiro-Inositol: These are the two most commonly used forms of inositol in supplements. Myo-inositol is the most abundant form and is widely used for its benefits in improving insulin sensitivity and hormonal balance. D-chiro-inositol is another important form, particularly effective in regulating insulin and androgen levels. The combination of these two forms is often used to maximize the therapeutic benefits, especially for conditions like PCOS.
6. Inositol Hexanicotinate: This form is a combination of inositol and niacin (vitamin B3) and is often used for its lipid-lowering effects. Inositol hexanicotinate provides the benefits of both inositol and niacin, making it useful for improving cholesterol levels and supporting cardiovascular health.

In summary, inositol comes in various forms, including powder, capsules, tablets, liquid, combined formulations, and specific isomers like Myo-inositol and D-chiro-inositol. Each form offers unique advantages, allowing individuals to choose the most suitable option based on their health needs and preferences. Always consult with a healthcare provider to determine the most appropriate form and dosage for your specific situation.

The efficacy of inositol is largely attributed to its key sub-compounds, primarily Myo-inositol and D-chiro-inositol. These two isomers play critical roles in various physiological processes and are often used in combination to maximize therapeutic benefits. Understanding the unique functions of these sub-compounds can help elucidate their importance in different health applications.

1. Myo-Inositol: Myo-inositol is the most abundant and well-studied form of inositol. It serves as a crucial component in the phosphatidylinositol signaling pathway, which is involved in cellular communication and regulation. Myo-inositol is particularly effective in improving insulin sensitivity and is widely used for managing conditions like polycystic ovary syndrome (PCOS) and metabolic syndrome. A study published in "Fertility and Sterility" demonstrated that Myo-inositol supplementation improved oocyte quality and ovulation rates in women with PCOS. Additionally, Myo-inositol has been shown to reduce symptoms of anxiety and depression by modulating neurotransmitter systems, including serotonin signaling.
2. D-chiro-Inositol: D-chiro-inositol is another important isomer that plays a significant role in insulin signaling and glucose metabolism. It is particularly effective in reducing insulin resistance and lowering blood glucose levels. D-chiro-inositol works by enhancing the activity of insulin receptors and facilitating glucose uptake into cells. Research published in "Clinical Nutrition" highlighted the benefits of D-chiro-inositol in improving glycemic control and insulin sensitivity in individuals with type 2 diabetes. In the context of PCOS, D-chiro-inositol has been shown to reduce androgen levels and improve hormonal balance, making it a valuable addition to therapeutic regimens for this condition.
3. Combination of Myo-Inositol and D-chiro-Inositol: The combination of Myo-inositol and D-chiro-inositol in a 40:1 ratio has been shown to be particularly effective for managing PCOS and other metabolic conditions. This ratio mimics the natural physiological balance found in the human body and maximizes the therapeutic benefits of both isomers. Studies have demonstrated that this combination can improve insulin sensitivity, reduce testosterone levels, and enhance ovulatory function more effectively than either isomer alone. For example, a study in the "European Review for Medical and Pharmacological Sciences" found that the 40:1 combination significantly improved metabolic and hormonal parameters in women with PCOS.
4. Inositol Hexanicotinate: Although not as commonly discussed, inositol hexanicotinate is a compound that combines inositol with niacin (vitamin B3). This form is often used for its lipid-lowering effects and is beneficial for improving cholesterol levels. It provides the benefits of both inositol and niacin, supporting cardiovascular health and reducing the risk of atherosclerosis.
5. Inositol Phosphates: Inositol phosphates, such as inositol triphosphate (IP3) and inositol hexakisphosphate (IP6), are derivatives of inositol that play crucial roles in cellular signaling and regulation. IP3 is involved in the release of calcium ions from intracellular stores, which is essential for various cellular functions, including muscle contraction and neurotransmitter release. IP6, also known as phytic acid, has antioxidant properties and is believed to have potential anti-cancer benefits. These inositol phosphates contribute to the overall efficacy of inositol by supporting cellular health and function.

In summary, the critical sub-compounds of inositol, particularly Myo-inositol and D-chiro-inositol, play essential roles in its efficacy for various health conditions. The combination of these isomers, along with other derivatives like inositol hexanicotinate and inositol phosphates, enhances the therapeutic potential of inositol. Understanding the unique functions of these sub-compounds can help optimize their use in promoting overall health and well-being.

Inositol is a versatile compound known by various names, abbreviations, and chemical terms. Understanding these different names and terms can help in identifying the compound across various contexts and products. Here are some of the common synonyms, misspellings, and related terms for inositol:

1. Myo-Inositol: This is the most common and biologically active form of inositol. It is often referred to simply as "inositol" in many contexts, but specifying "Myo-inositol" is crucial when discussing its specific therapeutic applications.
2. D-chiro-Inositol: Another important isomer of inositol, known for its role in insulin signaling and glucose metabolism. It is often used in combination with Myo-inositol, particularly in the management of polycystic ovary syndrome (PCOS).
3. Inositol Hexanicotinate: Also known as "inositol niacinate" or "inositol nicotinate," this compound combines inositol with niacin (vitamin B3) and is used for its lipid-lowering effects.
4. Phytic Acid: Also known as "inositol hexakisphosphate" or "IP6," phytic acid is a derivative of inositol found in plant seeds and grains. It has antioxidant properties and is sometimes used for its potential anti-cancer benefits.
5. Vitamin B8: Although not officially recognized as a vitamin, inositol is sometimes referred to as "Vitamin B8" due to its role in cellular functions and its inclusion in the B-vitamin complex.
6. C6H12O6: This is the chemical formula for inositol, representing its molecular composition of six carbon atoms, twelve hydrogen atoms, and six oxygen atoms.
7. Cyclohexanehexol: Another chemical name for inositol, referring to its structure as a six-carbon ring with six hydroxyl groups attached.
8. Misspellings and Abbreviations: Common misspellings and abbreviations include "inosotol," "inositol," "inosatol," and "inosito." While these misspellings are incorrect, they are often seen in informal contexts or consumer inquiries.
9. Other Names and Terms:
   • Scyllo-Inositol: An isomer of inositol that has been studied for its potential benefits in neurodegenerative diseases like Alzheimer's disease.
   • D-Pinitol: A derivative of inositol found in certain plants, known for its insulin-mimetic properties.
   • Inosite: An older term sometimes used to refer to inositol, though it is less common in contemporary scientific literature.
10. Trade Names and Supplement Names: Inositol supplements may be marketed under various brand names and proprietary formulations. These products often include terms like "Myo-inositol," "D-chiro-inositol," or combinations such as "Ovasitol" (a blend of Myo-inositol and D-chiro-inositol).

In summary, inositol is known by various names, abbreviations, and chemical terms, including Myo-inositol, D-chiro-inositol, inositol hexanicotinate, phytic acid (IP6), Vitamin B8, and cyclohexanehexol. Understanding these different terms can help in identifying inositol in various contexts and ensuring accurate information when discussing its benefits and applications.

When selecting an inositol supplement, it's crucial to examine the label carefully to ensure product quality and efficacy. Here are the key elements to look for on the label:

1. Type of Inositol: The label should clearly specify the type of inositol included in the supplement. Myo-inositol and D-chiro-inositol are the most commonly used forms, each with specific health benefits. For conditions like polycystic ovary syndrome (PCOS), a combination of Myo-inositol and D-chiro-inositol in a 40:1 ratio is often recommended. Ensuring that the correct form and ratio are specified on the label is essential for achieving the desired therapeutic effects.
2. Dosage: Verify the dosage per serving listed on the label. The appropriate dosage can vary depending on the condition being treated. For example, common dosages include 2 to 4 grams per day for PCOS and metabolic health, and up to 12-18 grams per day for mental health conditions like anxiety and depression. Ensure the product provides a dosage that aligns with the recommendations for your specific health needs.
3. Purity and Ingredients: Check for the presence of other ingredients or fillers. High-quality supplements will often list "pure inositol" or only necessary excipients. Avoid products with unnecessary additives, artificial colors, or preservatives. Look for labels that state the product is free from common allergens such as gluten, dairy, soy, and artificial additives.
4. Third-Party Testing: Look for indications that the product has undergone third-party testing or certification. This can include seals or logos from reputable organizations like NSF International, USP (United States Pharmacopeia), or ConsumerLab. Third-party testing ensures that the supplement meets quality, purity, and potency standards.
5. Manufacturing Standards: Ensure that the supplement is manufactured in a facility that follows Good Manufacturing Practices (GMP). This information is often indicated on the label or the company's website. GMP certification ensures that the product is produced in a clean, controlled environment and meets specific quality standards.
6. Source of Inositol: Some labels may specify the source of inositol. Inositol can be derived from various natural sources, including corn, rice, and other plants. Knowing the source can be important for individuals with specific dietary preferences or restrictions.
7. Expiration Date: Check the expiration date to ensure the product is fresh and will maintain its potency throughout its shelf life. Avoid purchasing supplements that are close to or past their expiration date.
8. Certifications and Claims: Look for any additional certifications or claims that indicate product quality, such as "non-GMO," "organic," "vegan," or "cruelty-free." These certifications can provide assurance regarding the ethical and environmental standards of the product.
9. Serving Size and Instructions: Review the serving size and usage instructions to ensure they align with your intended use. Some products may require multiple servings per day, so understanding the recommended usage is important for proper supplementation.
10. Brand Reputation: While not directly on the label, researching the brand's reputation can provide insight into product quality. Look for brands with positive reviews, transparent sourcing and manufacturing practices, and a history of producing high-quality supplements.

In summary, when selecting an inositol supplement, carefully examine the label for the type of inositol, dosage, purity, third-party testing, manufacturing standards, source, expiration date, certifications, serving size, and brand reputation. These factors will help ensure that you choose a high-quality product that meets your specific health needs. Always consult with a healthcare provider before starting any new supplement regimen.

The information provided on this website, including any text, images, or other material contained within, is for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. This page was created by the SuppCo editiorial team, with AI summarization tools, including data from but not limited to following studies:

1. K. Brunst, P. Ryan, M. Altaye, K. Yolton, T. Maloney, Travis Beckwith, G. Lemasters, K. Cecil (2019). Myo-inositol mediates the effects of traffic-related air pollution on generalized anxiety symptoms at age 12 years.. Environmental research, 175,
   71-78 . Link: 10.1016/j.envres.2019.05.009
2. T. Cantelmi, E. Lambiase, V. Unfer, R. Gambioli, V. Unfer (2021). Inositol treatment for psychological symptoms in Polycystic Ovary Syndrome women.. European review for medical and pharmacological sciences, 25 5,
   2383-2389 . Link: 10.26355/eurrev_202103_25278
3. H. Cohen, M. Kotler, Z. Kaplan, M. Matar, O. Kofman, R. Belmaker (2005). Inositol has behavioral effects with adaptation after chronic administration. Journal of Neural Transmission, 104, 299-305. Link: 10.1007/BF01273190
4. O. Kofman, H. Einat, H. Cohen, H. Tenne, C. Shoshana (2000). The anxiolytic effect of chronic inositol depends on the baseline level of anxiety. Journal of Neural Transmission, 107, 241-253. Link: 10.1007/s007020050020
5. Y. Bersudsky, H. Einat, Z. Stahl, R. Belmaker (1999). Epi-Inositol and inositol depletion: Two new treatment approaches in affective disorder. Current Psychiatry Reports, 1, 141-147. Link: 10.1007/S11920-999-0023-Z
6. H. Einat, A. Shaldubina, R. H. Belmaker (2000). Epi‐inositol: A potential antidepressant. Drug Development Research, 50, . Link: 10.1002/1098-2299(200007/08)50:3/4<309::AID-DDR14>3.0.CO;2-I
7. H. Einat, R. Belmaker (2001). The effects of inositol treatment in animal models of psychiatric disorders.. Journal of affective disorders, 62 1-2,
   113-21 . Link: 10.1016/S0165-0327(00)00355-4
8. Matthew Taylor, Heather Wilder, Zubin Bhagwagar, John R. Geddes (2004). Inositol for depressive disorders.. The Cochrane database of systematic reviews, 2,
   CD004049 . Link: 10.1002/14651858.CD004049.PUB2
9. J. Benjamin, H. Nemetz, M. Fux, I. Bleichman, G. Agam (1997). Acute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorder.. Journal of psychiatric research, 31 4,
   489-95 . Link: 10.1016/S0022-3956(97)00021-6
10. H. Einat, Ziva Elkabaz-Shwortz, H. Cohen, O. Kofman, R. Belmaker (1998). Chronic epi-inositol has an anxiolytic-like effect in the plus-maze model in rats.. The international journal of neuropsychopharmacology, 1 1,
    31-34 . Link: 10.1017/S1461145798001035
11. M. Showell, Rebecca Mackenzie-Proctor, V. Jordan, Ruth Hodgson, C. Farquhar (2016). Inositol for subfertile women with polycystic ovary syndrome.. The Cochrane database of systematic reviews, 12,
    CD012378 . Link: 10.1002/14651858.CD012378.pub2
12. L. Nazari, S. Salehpour, S. Hosseini, Nasrin Sharkhiz, E. Azizi, Teibeh Hashemi, R. Ghodssi-ghassemabadi (2020). Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: a randomized controlled trial.. Journal of gynecology obstetrics and human reproduction, ,
    101698 . Link: 10.1016/j.jogoh.2020.101698
13. A. Laganà, S. Garzon, J. Casarin, M. Franchi, F. Ghezzi (2018). Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach. Trends in Endocrinology & Metabolism, 29, 768-780. Link: 10.1016/j.tem.2018.09.001
14. P. Bhide, J. Pundir, A. Gudi, Amit Shah, R. Homburg, G. Acharya (2019). The effect of myo‐inositol/di‐chiro‐inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta‐analysis. Acta Obstetricia et Gynecologica Scandinavica, 98, 1235 - 1244. Link: 10.1111/aogs.13625
15. Azadeh Akbari Sene, Azam Tabatabaie, Hossein Nikniaz, A. Alizadeh, K. Sheibani, Mona Mortezapour Alisaraie, Maryam Tabatabaie, M. Ashrafi, F. Amjadi (2019). The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial. Archives of Gynecology and Obstetrics, 299, 1701-1707. Link: 10.1007/s00404-019-05111-1
16. P. Beemster, P. Groenen, R. Steegers-Theunissen (2002). Involvement of inositol in reproduction.. Nutrition reviews, 60 3,
    80-7 . Link: 10.1301/00296640260042748
17. A. Calogero, G. Gullo, S. Vignera, R. Condorelli, A. Vaiarelli (2015). Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double‐blind randomized placebo‐controlled study. Andrology, 3, . Link: 10.1111/andr.12025
18. R. Gambioli, G. Forte, G. Buzzaccarini, V. Unfer, A. Laganà (2021). Myo-Inositol as a Key Supporter of Fertility and Physiological Gestation. Pharmaceuticals, 14, . Link: 10.3390/ph14060504
19. S. Mohammadi, F. Eini, F. Bazarganipour, S. Taghavi, Maryam Azizi Kutenaee (2021). The effect of Myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial. Reproductive Biology and Endocrinology : RB&E, 19, . Link: 10.1186/s12958-021-00741-0
20. E. Papaleo, V. Unfer, J. Baillargeon, F. Fusi, F. Occhi, L. De Santis (2009). Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.. Fertility and sterility, 91 5,
    1750-4 . Link: 10.1016/j.fertnstert.2008.01.088
21. A. Wojciechowska, A. Osowski, M. Jóźwik, R. Górecki, A. Rynkiewicz, J. Wojtkiewicz (2019). Inositols’ Importance in the Improvement of the Endocrine–Metabolic Profile in PCOS. International Journal of Molecular Sciences, 20, . Link: 10.3390/ijms20225787
22. Z. Kamenov, A. Gateva (2020). Inositols in PCOS. Molecules, 25, . Link: 10.3390/molecules25235566
23. T. Cantelmi, E. Lambiase, V. Unfer, R. Gambioli, V. Unfer (2021). Inositol treatment for psychological symptoms in Polycystic Ovary Syndrome women.. European review for medical and pharmacological sciences, 25 5,
    2383-2389 . Link: 10.26355/eurrev_202103_25278
24. Garene A. Matossian, Isabella M. Buklarewicz, Vaneeza A. Moosa (2023). The Effects of Metformin and Myo-Inositol on Hyperandrogenism, Insulin Sensitivity, and Fertility in Polycystic Ovary Syndrome: A Literature Review. Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal, , . Link: 10.26685/urncst.483
25. A. Genazzani (2016). Inositol as putative integrative treatment for PCOS.. Reproductive biomedicine online, 33 6,
    770-780 . Link: 10.1016/j.rbmo.2016.08.024
26. D. Costantino, G. Minozzi, F. Minozzi, C. Guaraldi (2009). Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.. European review for medical and pharmacological sciences, 13 2,
    105-10 . Link:
27. G. Dona', C. Sabbadin, C. Fiore, M. Bragadin, F. Giorgino, E. Ragazzi, G. Clari, L. Bordin, D. Armanini (2012). Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome.. European journal of endocrinology, 166 4,
    703-10 . Link: 10.1530/EJE-11-0840
28. Z. Abdul, Hameed Ibrahim ⃰ ،Manal, Khaled, Abdulrida, Basil Razoqi, Article Info (2023). Assessment of Symptoms, Pregnancy Outcome, and Health-Related Quality of Life among PCOS women Treated with Myo inositol and Metformin. Al Mustansiriyah Journal of Pharmaceutical Sciences, , . Link: 10.32947/ajps.v23i3.1045
29. A. Laganà, Paola Rossetti, M. Buscema, S. La Vignera, R. Condorelli, G. Gullo, R. Granese, O. Triolo (2016). Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols. International Journal of Endocrinology, 2016, . Link: 10.1155/2016/6306410
30. V. Unfer, F. Facchinetti, B. Orrù, B. Giordani, J. Nestler (2017). Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections, 6, 647 - 658. Link: 10.1530/EC-17-0243
31. A. Özturan, S. Arslan, B. Kocaadam, Emine S. Elibol, İdil İmamoğlu, M. Karadağ (2019). Effect of inositol and its derivatives on diabetes: a systematic review. Critical Reviews in Food Science and Nutrition, 59, 1124 - 1136. Link: 10.1080/10408398.2017.1392926
32. Marine L. Croze, Roxane E. Vella, Nicolas J. Pillon, H. Soula, Lilas Hadji, M. Guichardant, C. Soulage (2013). Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice.. The Journal of nutritional biochemistry, 24 2,
    457-66 . Link: 10.1016/j.jnutbio.2012.01.008
33. A. Bevilacqua, M. Bizzarri (2018). Inositols in Insulin Signaling and Glucose Metabolism. International Journal of Endocrinology, 2018, . Link: 10.1155/2018/1968450
34. D. Costantino, G. Minozzi, F. Minozzi, C. Guaraldi (2009). Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.. European review for medical and pharmacological sciences, 13 2,
    105-10 . Link:
35. S. Foster, F. Omoruyi, J. Bustamante, R. A. Lindo, L. Dilworth (2016). The effect of combined inositol hexakisphosphate and inositol supplement in streptozotocin‐induced type 2 diabetic rats. International Journal of Experimental Pathology, 97, . Link: 10.1111/iep.12210
36. Marine L. Croze, C. Soulage (2013). Potential role and therapeutic interests of myo-inositol in metabolic diseases.. Biochimie, 95 10,
    1811-27 . Link: 10.1016/j.biochi.2013.05.011
37. Chunxue Fan, Weishi Liang, Min Wei, Xiangbo Gou, Shuying Han, Jing Bai (2020). Effects of D-Chiro-Inositol on Glucose Metabolism in db/db Mice and the Associated Underlying Mechanisms. Frontiers in Pharmacology, 11, . Link: 10.3389/fphar.2020.00354
38. Xuelian Yin, Fei‐fei Guo, Xiangrong Sun, Luo Xu (2018). Effects of Muscle Inositol on Fasting Blood Glucose in Patients with type 2 Diabetes, Blood Glucose 2 h after Meal, and Glycosylated Hemoglobin. International journal of sciences, 4, 1-3. Link: 10.18483/ijsci.1786
39. C. Bañuls, S. Rovira-Llopis, R. Falcón, S. Veses, Nuria Monzó, V. M. Víctor, M. Rocha, A. Hernández-Mijares (2016). Chronic consumption of an inositol-enriched carob extract improves postprandial glycaemia and insulin sensitivity in healthy subjects: A randomized controlled trial.. Clinical nutrition, 35 3,
    600-7 . Link: 10.1016/j.clnu.2015.05.005
40. I. Miñambres, G. Cuixart, Anna Gonçalves, R. Corcoy (2017). Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials.. Clinical nutrition, 38 3,
    1146-1152 . Link: 10.1016/j.clnu.2018.06.957
41. A. Özturan, S. Arslan, B. Kocaadam, Emine S. Elibol, İdil İmamoğlu, M. Karadağ (2019). Effect of inositol and its derivatives on diabetes: a systematic review. Critical Reviews in Food Science and Nutrition, 59, 1124 - 1136. Link: 10.1080/10408398.2017.1392926
42. Sogol Hashemi Tari, M. Sohouli, Abolfazl Lari, S. Fatahi, S. T. Rahideh (2021). The effect of inositol supplementation on blood pressure: A systematic review and meta-analysis of randomized-controlled trials.. Clinical nutrition ESPEN, 44,
    78-84 . Link: 10.1016/j.clnesp.2021.06.017
43. V. S. Voruganti, Faustina Jeyaraj, Brea Nance, B. Mass, A. Williams, Masha R Block, K. Kavanagh (2022). A Pilot Assessment of Inosine Effects on Blood Pressure in Vervet Monkeys. Current Developments in Nutrition, 6, 52 - 52. Link: 10.1093/cdn/nzac047.052
44. S. Sylla, S. P. Ojalvo, J. Komorowski (2018). An Evaluation of the Effect of Inositol‐Stabilized Arginine Silicate on Heart Rate and Blood Pressure. The FASEB Journal, 32, . Link: 10.1096/fasebj.2018.32.1_supplement.724.12
45. D. Menichini, Mesk A. Alrais, Chen Liu, Yang Xia, S. Blackwell, F. Facchinetti, B. Sibai, M. Longo (2020). Maternal supplementation of inositols, fucoxanthin, and hydroxytyrosol in pregnant murine models of hypertension.. American journal of hypertension, , . Link: 10.1093/ajh/hpaa041
46. D. Giordano, F. Corrado, A. Santamaria, Simona Quattrone, B. Pintaudi, A. Di Benedetto, R. D’Anna (2011). Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause, 18, 102-104. Link: 10.1097/gme.0b013e3181e8e1b1
47. S. Bernier, G. Guillemette (1993). Increased inositol 1,4,5-trisphosphate binding capacity in vascular smooth muscle of spontaneously hypertensive rats.. American journal of hypertension, 6 3 Pt 1,
    217-25 . Link: 10.1093/AJH/6.3.217
48. D. Costantino, G. Minozzi, F. Minozzi, C. Guaraldi (2009). Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.. European review for medical and pharmacological sciences, 13 2,
    105-10 . Link:
49. M. Longo, Mesk A. Alrais, E. Tamayo, F. Ferrari, F. Facchinetti, J. Refuerzo, S. Blackwell, B. Sibai (2019). Vascular and metabolic profiles in offspring born to pregnant mice with metabolic syndrome treated with inositols. American Journal of Obstetrics and Gynecology, 220, 279.e1–279.e9. Link: 10.1016/j.ajog.2018.11.1101
50. S. Lam, A. Mcwilliams, J. Leriche, C. MacAulay, L. Wattenberg, E. Szabo (2006). A Phase I Study of myo-Inositol for Lung Cancer Chemoprevention. Cancer Epidemiology Biomarkers & Prevention, 15, 1526 - 1531. Link: 10.1158/1055-9965.EPI-06-0128
51. Matthew Taylor, Heather Wilder, Zubin Bhagwagar, John R. Geddes (2004). Inositol for depressive disorders.. The Cochrane database of systematic reviews, 2,
    CD004049 . Link: 10.1002/14651858.CD004049.PUB2
52. Joseph Levine, Yoram Barak, M. Gonzalves, H. Szor, Avner Elizur, Ora Kofman, R. Belmaker (1995). Double-blind, controlled trial of inositol treatment of depression.. The American journal of psychiatry, 152 5,
    792-4 . Link: 10.1176/AJP.152.5.792
53. A. Eden Evins, C. Demopulos, Iftah Yovel, Melissa A. Culhane, J. Ogutha, Louisa D. Grandin, A. Nierenberg, G. Sachs (2006). Inositol augmentation of lithium or valproate for bipolar depression.. Bipolar disorders, 8 2,
    168-74 . Link: 10.1111/J.1399-5618.2006.00303.X
54. J. Levine (1997). Controlled trials of inositol in psychiatry. European Neuropsychopharmacology, 7, 147-155. Link: 10.1016/S0924-977X(97)00409-4
55. K. Chengappa, Joseph Levine, Samuel Gershon, A. Mallinger, Antonio Y. Hardan, A. H. Vagnucci, Bruce G. Pollock, James F. Luther, Joan Buttenfield, Steve Verfaille, David J. Kupfer (2000). Inositol as an add-on treatment for bipolar depression.. Bipolar disorders, 2 1,
    47-55 . Link: 10.1034/J.1399-5618.2000.020107.X
56. H. Einat, H. Karbovski, J. Korik, D. Tsalah, R. Belmaker (1999). Inositol reduces depressive-like behaviors in two different animal models of depression. Psychopharmacology, 144, 158-162. Link: 10.1007/s002130050989
57. J. Levine, Alex Mishori, Michael Susnosky, Michael Martin, R. Belmaker (1999). Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biological Psychiatry, 45, 270-273. Link: 10.1016/S0006-3223(98)00145-0
58. J. Benjamin, G. Agam, J. Levine, Y. Bersudsky, O. Kofman, R. Belmaker (1995). Inositol treatment in psychiatry.. Psychopharmacology bulletin, 31 1,
    167-75 . Link:
59. M. Fux, J. Levine, A. Aviv, R. Belmaker (1996). Inositol treatment of obsessive-compulsive disorder.. The American journal of psychiatry, 153 9,
    1219-21 . Link: 10.1176/AJP.153.9.1219
60. B. Nemets, A. Mishory, J. Levine, R. Belmaker (1999). Inositol addition does not improve depression in SSRI treatment failures. Journal of Neural Transmission, 106, 795-798. Link: 10.1007/s007020050200
61. Mr. Abhijit V. Tambe, Mr. Rohit H. Phapale, Mr. Prathmesh S. Shingote, Prof. Sagar E. Tambe (2022). Formulation and Evaluation of Herbal Shampoo from Fermented Rice Water and its Anti-Fungal Activity. International Journal of Advanced Research in Science, Communication and Technology, , . Link: 10.48175/ijarsct-4570
62. J. Komorowski, S. P. Ojalvo, S. Sylla, D. Cicek, B. Demir, C. Orhan, M. Tuzcu, N. Şahin, K. Şahin (2019). The Effect of a Combination of an Arginine Silicate Complex and Magnesium Biotinate on Hair and Nail Growth in Rats (P06-026-19).. Current developments in nutrition, 3 Suppl 1, . Link: 10.1093/cdn/nzz031.P06-026-19
63. T. J. Cunha, S. Kirkwood, P. Phillips, G. Bohstedt (1943). Effect of Inositol upon Rat Alopecia.∗. Proceedings of the Society for Experimental Biology and Medicine, 54, 236 - 238. Link: 10.3181/00379727-54-14383
64. S.A. Lee, M. Bedford (2016). Inositol - An effective growth promotor?. World's Poultry Science Journal, 72, 743 - 760. Link: 10.1017/S0043933916000660
65. Harry Eagle, Vance I. Oyama, Mina Levy, Aaron E. Freeman (1956). Myo-Inositol as an essential growth factor for normal and malignant human cells in tissue culture.. The Journal of biological chemistry, 226 1,
    191-205 . Link: 10.1126/SCIENCE.123.3202.845-A
66. Kyung-A Hwang, Y. Hwang, Min‐ho Lee, Nari Kim, S. Roh, Y. Lee, C. Kim, Jeung-Hoon Lee, Kyung-Chul Choi (2011). Adenosine stimulates growth of dermal papilla and lengthens the anagen phase by increasing the cysteine level via fibroblast growth factors 2 and 7 in an organ culture of mouse vibrissae hair follicles.. International journal of molecular medicine, 29 2,
    195-201 . Link: 10.3892/ijmm.2011.817
67. T. Ogunribido, M. Bedford, O. Adeola, K. Ajuwon (2022). Effect of supplemental myo-inositol on growth performance and apparent total tract digestibility of weanling piglets fed reduced protein high phytate diets and intestinal epithelial cell proliferation and function.. Journal of animal science, , . Link: 10.1093/jas/skac187
68. Hang Lu, A. Cowieson, J. Wilson, K. Ajuwon, O. Adeola (2019). Extra-phosphoric effects of super dosing phytase on growth performance of pigs is not solely due to release of myo-inositol.. Journal of animal science, , . Link: 10.1093/jas/skz232
69. S ‐P Pan, Xiaobo Yan, Xiao‐hui Dong, Tao Li, Xiangxiang Suo, Hao Liu, B. Tan, Shuang Zhang, Zhihao Li, Yuan‐zhi Yang, Hai-tao Zhang (2022). Influence of Dietary Inositol Supplementation on Growth, Liver Histology, Lipid Metabolism, and Related Genes Expression on Juvenile Hybrid Grouper (♀ Epinephelus fuscoguttatus × ♂ E. lanceolatu) Fed High-Lipid Diets. Aquaculture Nutrition, , . Link: 10.1155/2022/6743690
70. H. Oura, Masato Iino, Y. Nakazawa, M. Tajima, R. Ideta, Y. Nakaya, S. Arase, J. Kishimoto (2008). Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: A pilot, double‐blind, randomized, placebo‐controlled trial. The Journal of Dermatology, 35, . Link: 10.1111/j.1346-8138.2008.00564.x
71. Xianshan Guo, Shizhe Guo, Zhiyi Miao, Zhen Li, Hongya Zhang (2017). Myo-inositol lowers the risk of developing gestational diabetic mellitus in pregnancies: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.. Journal of diabetes and its complications, 32 3,
    342-348 . Link: 10.1016/j.jdiacomp.2017.07.007
72. G. Assimakopoulow, V. Pergialiotis, A. Kallergi, P. Antsaklis, M. Sindos, E. Voyatzi, M. Theodora, E. Anastasiou, G. Daskalakis (2020). VP47.07: Effect of dietary myo‐inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: interim analysis of a randomised controlled trial. Ultrasound in Obstetrics & Gynecology, 56, . Link: 10.1002/uog.23164
73. R. D’Anna, A. Scilipoti, D. Giordano, C. Caruso, M. Cannata, M. L. Interdonato, F. Corrado, A. Di Benedetto (2013). myo-Inositol Supplementation and Onset of Gestational Diabetes Mellitus in Pregnant Women With a Family History of Type 2 Diabetes. Diabetes Care, 36, 854 - 857. Link: 10.2337/dc12-1371
74. Chiamaka Esther Amaefule, Zoe Drymoussi, J. Dodds, L. Sweeney, E. Pizzo, J. Daru, J. Robson, L. Poston, A. Khalil, J. Myers, A. Harden, G. Hitman, K. Khan, J. Zamora, M. S. Huda, S. Thangaratinam (2018). Effectiveness and acceptability of myo-inositol nutritional supplement in the prevention of gestational diabetes (EMmY): a protocol for a randomised, placebo-controlled, double-blind pilot trial. BMJ Open, 8, . Link: 10.1136/bmjopen-2018-022831
75. C. Celentano, B. Matarrelli, G. Pavone, E. Vitacolonna, P. A. Mattei, V. Berghella, M. Liberati (2020). The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial. The Journal of Maternal-Fetal & Neonatal Medicine, 33, 743 - 751. Link: 10.1080/14767058.2018.1500545
76. Chiamaka Esther Amaefule, Zoe Drymoussi, F. J. Gonzalez Carreras, Maria del Carmen Pardo Llorente, D. Lanz, J. Dodds, L. Sweeney, Elena Pizzo, Amy Thomas, James Heighway, J. Daru, Soha Sobhy, L. Poston, A. Khalil, J. Myers, A. Harden, G. Hitman, K. Khan, J. Zamora, T. Pérez, M. S. Huda, S. Thangaratinam (2022). Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study. BMJ Open, 12, . Link: 10.1136/bmjopen-2021-050110
77. Ibrahim Ibrahim, Hala Abdullahi, Yassin Fagier, O. Ortashi, Annalisa Terrangera, Gbemisola O. Okunoye (2022). Effect of antenatal dietary myo-inositol supplementation on the incidence of gestational diabetes mellitus and fetal outcome: protocol for a double-blind randomised controlled trial. BMJ Open, 12, . Link: 10.1136/bmjopen-2021-055314
78. Tineke J Crawford, C. Crowther, J. Alsweiler, Julie Brown (2015). Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes.. The Cochrane database of systematic reviews, 12,
    CD011507 . Link: 10.1002/14651858.CD011507.pub2
79. Soana K Motuhifonua, Luling Lin, J. Alsweiler, Tineke J Crawford, C. Crowther (2023). Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes.. The Cochrane database of systematic reviews, 2,
    CD011507 . Link: 10.1002/14651858.CD011507.pub3
80. A. Santamaria, Angela Alibrandi, A. Benedetto, B. Pintaudi, F. Corrado, Fabio Facchinetti, R. D’Anna (2018). Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo‐inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology, 219, 300.e1–300.e6. Link: 10.1016/j.ajog.2018.05.018
81. C. Bañuls, S. Rovira-Llopis, R. Falcón, S. Veses, Nuria Monzó, V. M. Víctor, M. Rocha, A. Hernández-Mijares (2016). Chronic consumption of an inositol-enriched carob extract improves postprandial glycaemia and insulin sensitivity in healthy subjects: A randomized controlled trial.. Clinical nutrition, 35 3,
    600-7 . Link: 10.1016/j.clnu.2015.05.005
82. I. Miñambres, G. Cuixart, Anna Gonçalves, R. Corcoy (2017). Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials.. Clinical nutrition, 38 3,
    1146-1152 . Link: 10.1016/j.clnu.2018.06.957
83. M. Shokrpour, F. Foroozanfard, Faraneh Afshar Ebrahimi, Z. Vahedpoor, E. Aghadavod, A. Ghaderi, Z. Asemi (2019). Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecological Endocrinology, 35, 406 - 411. Link: 10.1080/09513590.2018.1540570
84. Haley Serra, Yi Li (2021). A Case Study of Inositol and Soluble Fiber Supplementation on Glycemic Control in an Overweight Subject. Obesity Research – Open Journal, , . Link: 10.17140/oroj-8-148
85. B. Pintaudi, G. Di Vieste, M. Bonomo (2016). The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes. International Journal of Endocrinology, 2016, . Link: 10.1155/2016/9132052
86. Meysam Zarezadeh, A. Dehghani, A. Faghfouri, Nima Radkhah, Mohammad Naemi Kermanshahi, F. Hamedi Kalajahi, Niyaz Mohammadzadeh Honarvar, Z. Ghoreishi, A. Ostadrahimi, Mehrangiz Ebrahimi Mamaghani (2021). Inositol supplementation and body mass index: A systematic review and meta‐analysis of randomized clinical trials. Obesity Science & Practice, 8, 387 - 397. Link: 10.1002/osp4.569
87. F. Facchinetti, P. Cavalli, A. Copp, R. D’Anna, Eleni A. Kandaraki, N. Greene, V. Unfer (2020). An update on the use of inositols in preventing gestational diabetes mellitus (GDM) and neural tube defects (NTDs). Expert Opinion on Drug Metabolism & Toxicology, 16, 1187 - 1198. Link: 10.1080/17425255.2020.1828344
88. C. Celentano, B. Matarrelli, G. Pavone, E. Vitacolonna, P. A. Mattei, V. Berghella, M. Liberati (2020). The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial. The Journal of Maternal-Fetal & Neonatal Medicine, 33, 743 - 751. Link: 10.1080/14767058.2018.1500545
89. J. A. Navarro, Juan Decara, D. Medina-Vera, Rubén Tovar, J. Suárez, J. Pavón, A. Serrano, M. Vida, A. Gutiérrez-Adán, Carlos Sanjuan, E. Baixeras, F. R. Fonseca (2020). D-Pinitol from Ceratonia siliqua Is an Orally Active Natural Inositol That Reduces Pancreas Insulin Secretion and Increases Circulating Ghrelin Levels in Wistar Rats. Nutrients, 12, . Link: 10.3390/nu12072030
90. Jingshu Wei, Jie Yan, Huixia Yang (2022). Inositol Nutritional Supplementation for the Prevention of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 14, . Link: 10.3390/nu14142831
91. Sébastien Tanaka, D. Couret, A. Tran-Dinh, J. Duranteau, P. Montravers, A. Schwendeman, O. Meilhac (2020). High-density lipoproteins during sepsis: from bench to bedside. Critical Care, 24, . Link: 10.1186/s13054-020-02860-3
92. T. Lüscher, U. Landmesser, A. von Eckardstein, A. Fogelman (2014). High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target.. Circulation research, 114 1,
    171-82 . Link: 10.1161/CIRCRESAHA.114.300935
93. T. Voyno-Yasenetskaya, L. Dobbs, S. Erickson, R. Hamilton (1993). Low density lipoprotein- and high density lipoprotein-mediated signal transduction and exocytosis in alveolar type II cells.. Proceedings of the National Academy of Sciences of the United States of America, 90, 4256 - 4260. Link: 10.1073/PNAS.90.9.4256
94. D. Mackay, J. Hathcock, E. Guarneri (2012). Niacin: chemical forms, bioavailability, and health effects.. Nutrition reviews, 70 6,
    357-66 . Link: 10.1111/j.1753-4887.2012.00479.x
95. S. Foster, L. Dilworth, Rory K. Thompson, R. Alexander-Lindo, F. Omoruyi (2017). Effects of combined inositol hexakisphosphate and inositol supplement on antioxidant activity and metabolic enzymes in the liver of streptozotocin-induced type 2 diabetic rats.. Chemico-biological interactions, 275,
    108-115 . Link: 10.1016/j.cbi.2017.07.024
96. V. Bochkov, V. Tkachuk, F. Bühler, T. Resink (1992). Phosphoinositide and calcium signalling responses in smooth muscle cells: comparison between lipoproteins, Ang II, and PDGF.. Biochemical and biophysical research communications, 188 3,
    1295-304 . Link: 10.1016/0006-291X(92)91372-W
97. S ‐P Pan, Xiaobo Yan, Xiao‐hui Dong, Tao Li, Xiangxiang Suo, Hao Liu, B. Tan, Shuang Zhang, Zhihao Li, Yuan‐zhi Yang, Hai-tao Zhang (2022). Influence of Dietary Inositol Supplementation on Growth, Liver Histology, Lipid Metabolism, and Related Genes Expression on Juvenile Hybrid Grouper (♀ Epinephelus fuscoguttatus × ♂ E. lanceolatu) Fed High-Lipid Diets. Aquaculture Nutrition, , . Link: 10.1155/2022/6743690
98. Panagiotis Fotakis, V. Kothari, D. G. Thomas, M. Westerterp, M. Molusky, E. Altin, Sandra Abramowicz, Nan Wang, Yi He, J. Heinecke, K. Bornfeldt, A. Tall (2019). Anti-Inflammatory Effects of HDL (High-Density Lipoprotein) in Macrophages Predominate Over Proinflammatory Effects in Atherosclerotic Plaques.. Arteriosclerosis, Thrombosis, & Vascular Biology, , . Link: 10.1161/ATVBAHA.119.313253
99. D. Myers, N. Fidge, H. Stanton, R. Larkins (1992). The effects of low density lipoprotein and high density lipoprotein on phosphoinositide hydrolysis in bovine aortic endothelial cells.. Atherosclerosis, 92 1,
    9-16 . Link: 10.1016/0021-9150(92)90004-Z
100. (2020). High Density Lipoprotein. Definitions, , . Link: 10.32388/fm20qo
101. A. Bevilacqua, M. Bizzarri (2018). Inositols in Insulin Signaling and Glucose Metabolism. International Journal of Endocrinology, 2018, . Link: 10.1155/2018/1968450
102. G. Muscogiuri, S. Palomba, A. Laganà, F. Orio (2016). Inositols in the Treatment of Insulin-Mediated Diseases. International Journal of Endocrinology, 2016, . Link: 10.1155/2016/3058393
103. C. Bañuls, S. Rovira-Llopis, R. Falcón, S. Veses, Nuria Monzó, V. M. Víctor, M. Rocha, A. Hernández-Mijares (2016). Chronic consumption of an inositol-enriched carob extract improves postprandial glycaemia and insulin sensitivity in healthy subjects: A randomized controlled trial.. Clinical nutrition, 35 3,
     600-7 . Link: 10.1016/j.clnu.2015.05.005
104. Jing He, Yan-li Zhang, Liping Wang, Xiao-chun Liu (2021). Impact of different stereoisomers of inositol on insulin sensitivity of gestational diabetes mellitus patients. World Journal of Clinical Cases, 9, 565 - 572. Link: 10.12998/wjcc.v9.i3.565
105. Yulong Zhang, Changzhong Li, Wenhui Zhang, Xiangqin Zheng, Xiujuan Chen (2020). Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model.. Journal of medicinal food, , . Link: 10.1089/jmf.2019.4580
106. Marine L. Croze, Roxane E. Vella, Nicolas J. Pillon, H. Soula, Lilas Hadji, M. Guichardant, C. Soulage (2013). Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice.. The Journal of nutritional biochemistry, 24 2,
     457-66 . Link: 10.1016/j.jnutbio.2012.01.008
107. I. Miñambres, G. Cuixart, Anna Gonçalves, R. Corcoy (2017). Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials.. Clinical nutrition, 38 3,
     1146-1152 . Link: 10.1016/j.clnu.2018.06.957
108. A. Saltiel, L. R. Sorbara-Cazan (1987). Inositol glycan mimics the action of insulin on glucose utilization in rat adipocytes.. Biochemical and biophysical research communications, 149 3,
     1084-92 . Link: 10.1016/0006-291X(87)90519-5
109. Federica Fraticelli, C. Celentano, I. A. Zecca, G. Vieste, B. Pintaudi, M. Liberati, M. Franzago, M. Nicola, E. Vitacolonna (2018). Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial. Acta Diabetologica, 55, 805-812. Link: 10.1007/s00592-018-1157-4
110. Marine L. Croze, C. Soulage (2013). Potential role and therapeutic interests of myo-inositol in metabolic diseases.. Biochimie, 95 10,
     1811-27 . Link: 10.1016/j.biochi.2013.05.011
111. A. Palatnik, Katerina Frolov, M. Fux, J. Benjamin (2001). Double-Blind, Controlled, Crossover Trial of Inositol Versus Fluvoxamine for the Treatment of Panic Disorder. Journal of Clinical Psychopharmacology, 21, 335-339. Link: 10.1097/00004714-200106000-00014
112. H. Einat, R. Belmaker (2001). The effects of inositol treatment in animal models of psychiatric disorders.. Journal of affective disorders, 62 1-2,
     113-21 . Link: 10.1016/S0165-0327(00)00355-4
113. J. Pettegrew, K. Panchalingam, J. Levine, R. McClure, S. Gershon, J. Yao (2001). Chronicmyo-inositol increases rat brain phosphatidylethanolamine plasmalogen. Biological Psychiatry, 49, 444-453. Link: 10.1016/S0006-3223(00)00953-7
114. H. Einat, A. Shaldubina, R. H. Belmaker (2000). Epi‐inositol: A potential antidepressant. Drug Development Research, 50, . Link: 10.1002/1098-2299(200007/08)50:3/4<309::AID-DDR14>3.0.CO;2-I
115. H. Einat, R. Belmaker, M. Kopilov, E. Klein, H. Gazawi, D. Ben-Shachar (1999). Rat brain monoamines after acute and chronic myo-inositol treatment. European Neuropsychopharmacology, 10, 27-30. Link: 10.1016/S0924-977X(99)00047-4
116. Y. Bersudsky, H. Einat, Z. Stahl, R. Belmaker (1999). Epi-Inositol and inositol depletion: Two new treatment approaches in affective disorder. Current Psychiatry Reports, 1, 141-147. Link: 10.1007/S11920-999-0023-Z
117. M. Fux, J. Levine, A. Aviv, R. Belmaker (1996). Inositol treatment of obsessive-compulsive disorder.. The American journal of psychiatry, 153 9,
     1219-21 . Link: 10.1176/AJP.153.9.1219
118. J. Levine (1997). Controlled trials of inositol in psychiatry. European Neuropsychopharmacology, 7, 147-155. Link: 10.1016/S0924-977X(97)00409-4
119. J. Benjamin, H. Nemetz, M. Fux, I. Bleichman, G. Agam (1997). Acute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorder.. Journal of psychiatric research, 31 4,
     489-95 . Link: 10.1016/S0022-3956(97)00021-6
120. J. Benjamin, J. Levine, M. Fux, A. Aviv, D. Levy, R. Belmaker (1995). Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.. The American journal of psychiatry, 152 7,
     1084-6 . Link: 10.1176/AJP.152.7.1084
121. G. Hoover, R. Nicolosi, J. Corey, M. el Lozy, K. C. Hayes (1978). Inositol deficiency in the gerbil: altered hepatic lipid metabolism and triglyceride secretion.. The Journal of nutrition, 108 10,
     1588-94 . Link: 10.1093/JN/108.10.1588
122. S ‐P Pan, Xiaobo Yan, Xiao‐hui Dong, Tao Li, Xiangxiang Suo, Hao Liu, B. Tan, Shuang Zhang, Zhihao Li, Yuan‐zhi Yang, Hai-tao Zhang (2022). Influence of Dietary Inositol Supplementation on Growth, Liver Histology, Lipid Metabolism, and Related Genes Expression on Juvenile Hybrid Grouper (♀ Epinephelus fuscoguttatus × ♂ E. lanceolatu) Fed High-Lipid Diets. Aquaculture Nutrition, , . Link: 10.1155/2022/6743690
123. M. Shokrpour, F. Foroozanfard, Faraneh Afshar Ebrahimi, Z. Vahedpoor, E. Aghadavod, A. Ghaderi, Z. Asemi (2019). Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecological Endocrinology, 35, 406 - 411. Link: 10.1080/09513590.2018.1540570
124. B. Gerloff, T. Herdt, W. W. Wells, R. Nachreiner, R. S. Emery (1986). Inositol and hepatic lipidosis. II. Effect of inositol supplementation and time from parturition on serum insulin, thyroxine and triiodothyronine and their relationship to serum and liver lipids in dairy cows.. Journal of animal science, 62 6,
     1693-702 . Link: 10.2527/JAS1986.6261693X
125. A. Pani, R. Giossi, D. Menichelli, V. A. Fittipaldo, F. Agnelli, E. Inglese, Alessandra Romandini, R. Roncato, B. Pintaudi, Francesco Del Sole, F. Scaglione (2020). Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. Nutrients, 12, . Link: 10.3390/nu12113379
126. E. Hayashi, T. Maeda, T. Tomita (1974). The effect of myo-inositol deficiency on lipid metabolism in rats. I. The alteration of lipid metabolism in myo-inositol deficient rats.. Biochimica et biophysica acta, 360 2,
     134-45 . Link: 10.1016/0005-2760(74)90163-5
127. M. Shimada, M. Hibino, A. Takeshita (2017). Dietary supplementation with myo-inositol reduces hepatic triglyceride accumulation and expression of both fructolytic and lipogenic genes in rats fed a high-fructose diet.. Nutrition research, 47,
     21-27 . Link: 10.1016/j.nutres.2017.08.005
128. B. Gerloff, T. Herdt, W. W. Wells, J. Liesman, R. S. Emery (1986). Inositol and hepatic lipidosis. I. Effect of inositol supplementation and time from parturition on liver and serum lipids in dairy cattle.. Journal of animal science, 62 6,
     1682-92 . Link: 10.2527/JAS1986.6261682X
129. D. Andersen, B. Holub (1976). The influence of dietary inositol on glyceride composition and synthesis in livers of rats fed different fats.. The Journal of nutrition, 106 4,
     529-36 . Link: 10.1093/JN/106.4.529
130. D. Costantino, G. Minozzi, F. Minozzi, C. Guaraldi (2009). Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.. European review for medical and pharmacological sciences, 13 2,
     105-10 . Link:
131. Meysam Zarezadeh, A. Dehghani, A. Faghfouri, Nima Radkhah, Mohammad Naemi Kermanshahi, F. Hamedi Kalajahi, Niyaz Mohammadzadeh Honarvar, Z. Ghoreishi, A. Ostadrahimi, Mehrangiz Ebrahimi Mamaghani (2021). Inositol supplementation and body mass index: A systematic review and meta‐analysis of randomized clinical trials. Obesity Science & Practice, 8, 387 - 397. Link: 10.1002/osp4.569
132. S. Esmaeilzadeh, Reza Ghadimi, S. Mashayekhamiri, D. Ma, Z. Basirat (2021). The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial.. Minerva obstetrics and gynecology, , . Link: 10.21203/RS.3.RS-260476/V1
133. Xianshan Guo, Shizhe Guo, Zhiyi Miao, Zhen Li, Hongya Zhang (2017). Myo-inositol lowers the risk of developing gestational diabetic mellitus in pregnancies: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.. Journal of diabetes and its complications, 32 3,
     342-348 . Link: 10.1016/j.jdiacomp.2017.07.007
134. F. Ferrari, F. Facchinetti, Alejandra E. Ontiveros, Robyn P. Roberts, M. Saade, S. Blackwell, B. Sibai, J. Refuerzo, M. Longo (2016). The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by metabolic syndrome and obesity.. American journal of obstetrics and gynecology, 215 4,
     503.e1-8 . Link: 10.1016/j.ajog.2016.05.038
135. Qiong Yang, Yao Zhang, Luqi Li, Jia Li, Yunlong Li, Lin Han, Min Wang (2022). D-chiro-Inositol facilitates adiponectin biosynthesis and activates the AMPKα/PPARs pathway to inhibit high-fat diet-induced obesity and liver lipid deposition.. Food & function, , . Link: 10.1039/d2fo00869f
136. S. Vitale, F. Corrado, S. Caruso, A. Di Benedetto, L. Giunta, A. Cianci, R. D’Anna (2020). Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes – a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition, 72, 670 - 679. Link: 10.1080/09637486.2020.1852191
137. J. L. Kenney, K. Carlberg (1995). The effect of choline and myo-inositol on liver and carcass fat levels in aerobically trained rats.. International journal of sports medicine, 16 2,
     114-6 . Link: 10.1055/S-2007-972975
138. S. Basciani, M. Nordio, S. Dinicola, V. Unfer, L. Gnessi (2023). Diet Plus Inositols, α-Lactalbumin and Gymnema sylvestre: The Successful Combo to Restore Body Weight and Metabolic Profile in Obese and Dysmetabolic Patients. Nutrients, 15, . Link: 10.3390/nu15143142
139. Sara Arefhosseini, Neda Roshanravan, Helda Tutunchi, Somayyeh Rostami, M. Khoshbaten, M. Ebrahimi‐Mameghani (2023). Myo-inositol supplementation improves cardiometabolic factors, anthropometric measures, and liver function in obese patients with non-alcoholic fatty liver disease. Frontiers in Nutrition, 10, . Link: 10.3389/fnut.2023.1092544
140. S ‐P Pan, Xiaobo Yan, Xiao‐hui Dong, Tao Li, Xiangxiang Suo, Hao Liu, B. Tan, Shuang Zhang, Zhihao Li, Yuan‐zhi Yang, Hai-tao Zhang (2022). Influence of Dietary Inositol Supplementation on Growth, Liver Histology, Lipid Metabolism, and Related Genes Expression on Juvenile Hybrid Grouper (♀ Epinephelus fuscoguttatus × ♂ E. lanceolatu) Fed High-Lipid Diets. Aquaculture Nutrition, , . Link: 10.1155/2022/6743690